CTIS2023-505334-10-00进行中（未招募）1 期
CP-START-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 271
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.CTIS2023-505334-10-01Marengo Therapeutics Inc.271
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
进行中（未招募）
1 期
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate CancerProstate CancerCTIS2023-504066-39-00Vaccitech PLC117
招募中
1 期
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC 1 in men with biochemical recurrence of prostate cancerCTIS2024-511430-12-00niversitaetsklinikum Tuebingen AöR56
招募中
1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid TumorsCTIS2022-500849-24-00Tolremo Therapeutics AG25